ASCO 2018
Summary of Presentation
May 16, 2018
ASCO: Accepted Presentations

- **Oral presentations**
  - DS-8201
  - Pexidartinib

- **Poster discussions**
  - U3-1402
  - Quizartinib
  - DS-3032

- **Poster presentations**
  - Trial-in-Progress
    - DS-8201
    - U3-1402
    - DS-1062
DS-8201 Ph1 study (multiple tumor) update
- Abstract No: 2501
- Oral presentation on June 1st, 2:45 PM – 5:45 PM

U3-1402 Ph1 study (breast cancer) update
- Abstract No: 2512
- Poster discussion on June 4th, 3:00 PM – 4:15 PM

Results will be updated at actual presentation
# ASCO Presentations: DS-8201

<table>
<thead>
<tr>
<th>DSI Compound</th>
<th>Presentation Type</th>
<th>Tumor Type</th>
<th>Lead Author</th>
<th>Title</th>
<th>Session</th>
</tr>
</thead>
</table>
| DS-8201      | Oral Presentation | HER2-positive solid tumors  | Hiroji Iwata    | Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts | Abstract No: 2501  
Session Name: Developmental Therapeutics- Clinical Pharmacology and Experimental Therapeutics  
Date: June 1, 2018  
Time: 2:45 PM – 5:45 PM  
Location: S406 |
| DS-8201      | Trial-in-Progress Poster Presentation | HER2-positive metastatic breast cancer | Jose Baselga | A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1 | Abstract No.: TPS1102  
Session Name: Breast Cancer- Metastatic  
Date: June 2, 2018  
Time: 8:00 AM – 11:30 AM  
Location: Hall A |
| DS-8201      | Trial-in-Progress Poster Presentation | HER2-positive gastric cancer | Kensei Yamaguchi | A randomized, phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer | Abstract No: TPS4133  
Session Name: Gastrointestinal (Noncolorectal) Cancer  
Date: June 3, 2018  
Time: 8:00 AM – 11:30 AM  
Location: Hall A |
### ASCO Presentations: ADC Franchise

<table>
<thead>
<tr>
<th>DSI Compound</th>
<th>Presentation Type</th>
<th>Tumor Type</th>
<th>Lead Author</th>
<th>Title</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U3-1402</strong></td>
<td>Poster Discussion</td>
<td>Metastatic breast cancer</td>
<td>Takahiro Kogawa</td>
<td>Single Agent Activity of U3-1402, a HER3-Targeting Antibody-Drug Conjugate, in Breast Cancer Patients: Phase 1 Dose Escalation Study</td>
<td>Abstract No: 2512 Session Name: Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics Poster Discussion Date: June 4, 2018 Time: 3:00 PM – 4:15 PM Location: S406</td>
</tr>
<tr>
<td><strong>U3-1402</strong></td>
<td>Trial-in-Progress Poster Presentation</td>
<td>Metastatic or unresectable EGFR-mutant NSCLC</td>
<td>Pasi A. Jänne</td>
<td>Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC</td>
<td>Abstract No.: TPS9110 Session Name: Lung Cancer—Non-Small Cell Metastatic Date: June 3, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A</td>
</tr>
<tr>
<td><strong>DS-1062</strong></td>
<td>Trial-in-Progress Poster Presentation</td>
<td>Advanced solid tumors</td>
<td>Jacob M. Sands</td>
<td>First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST)</td>
<td>Abstract No: TPS2605 Session Name: Developmental Therapeutics- Clinical Pharmacology and Experimental Therapeutics Date: June 4, 2018 Time: 8:00 AM – 11:30 AM Location: Hall A</td>
</tr>
<tr>
<td>DSI Compound</td>
<td>Presentation Type</td>
<td>Tumor Type</td>
<td>Lead Author</td>
<td>Title</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>------------</td>
<td>-------------</td>
<td>-------</td>
<td>---------</td>
</tr>
</tbody>
</table>
| Quizartinib | Poster Discussion | FLT3-ITD-mutated relapsed/refractory acute myeloid leukemia (AML) | Mark J. Levis | Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment | Abstract No.: 7017  
Session Name: Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allo transplant  
Poster Discussion  
Date: June 4, 2018  
Time: 11:30 AM – 12:45 PM  
Location: E450 |
| DS-3032      | Poster Discussion | Advanced solid tumors and lymphomas | Todd M. Bauer | A phase 1 study of the MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L) | Abstract No: 11514  
Session Name: Sarcoma  
Poster Discussion  
Date: June 2, 2018  
Time: 3:00 PM – 4:15 PM  
Location: S404  
Poster Session  
Date: June 2, 2018  
Time: 8:00 AM – 11:30 AM  
Location: Hall A |
<table>
<thead>
<tr>
<th>DSI Compound</th>
<th>Presentation Type</th>
<th>Tumor Type</th>
<th>Lead Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pexidartinib</td>
<td>Oral Presentation</td>
<td>Tenosynovial giant-cell tumor (TGCT)</td>
<td>William D. Tap</td>
<td>Final results of ENLIVEN: a global, double-blind, randomized, placebo-controlled, Phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT)</td>
</tr>
</tbody>
</table>

**Abstract No:** 11502  
**Session Name:** Sarcoma  
**Date:** June 4, 2018  
**Time:** 8:00 AM – 11:00 AM  
**Location:** S100a
Contact address regarding this material

Daiichi Sankyo Co., Ltd.
Corporate Communications Department
TEL: +81-3-6225-1126
Email: DaiichiSankyoIR@daiichisankyo.co.jp